TυHURA Biopharma

TυHURA Biopharma Obtains License for a New Supplemental Technology from West Virginia University, Conjugating Small Molecule Delta Receptor Inhibitors with Immunological Effectors Such as Checkpoint Inhibitors. Current-generation ADCs Utilize Antibodies as Targeting Agents and Cytotoxins as Payloads. In Contrast, TυHURA's First Bifunctional ADC Uses Highly Selective Small Molecule Inhibitors to Target Delta Receptors on MDSCs, with Immunological Effectors as the Payload. These Novel ADCs Are Bifunctional, Shutting Down MDSC Immunosuppression in the Tumor Microenvironment While Positioning Immunological Effectors, Such as Checkpoint Inhibitors, on MDSCs Within the Microenvironment, Enhancing Their Efficacy While Limiting the Indiscriminate Toxicity of Checkpoint-released Cytotoxic T Cells on Normal Tissues.